We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

161 hedge funds and large institutions have $1.15B invested in Allogene Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 64 increasing their positions, 51 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

357% more call options, than puts

Call options by funds: $1.27M | Put options by funds: $278K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

38% more capital invested

Capital invested by funds: $835M → $1.15B (+$314M)

25% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 51

5.93% more ownership

Funds ownership: 64.27% → 70.2% (+5.9%)

11% less funds holding

Funds holding: 180 → 161 (-19)

55% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 29

Holders
161
Holders Change
-19
Holders Change %
-10.56%
% of All Funds
2.71%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
13
Increased
64
Reduced
51
Closed
29
Calls
$1.27M
Puts
$278K
Net Calls
+$992K
Net Calls Change
+$520K

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$48.2M
2
EC
EcoR1 Capital
California
+$39.8M
3
Capital International Investors
Capital International Investors
California
+$33.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$14.7M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.5M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$22.5M
2
State Street
State Street
Massachusetts
-$19.7M
3
Norges Bank
Norges Bank
Norway
-$10.2M
4
Renaissance Technologies
Renaissance Technologies
New York
-$8.88M
5
Goldman Sachs
Goldman Sachs
New York
-$8.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$7.18M +$4.78M +538,699 +593%
Cerity Partners
27
Cerity Partners
New York
$6.85M -$888K -100,039 -14%
Invesco
28
Invesco
Georgia
$6.82M +$4.58M +515,612 +625%
N
29
Nuveen
North Carolina
$6.55M -$936K -105,469 -16%
Charles Schwab
30
Charles Schwab
California
$6.2M +$119K +13,450 +3%
Deutsche Bank
31
Deutsche Bank
Germany
$5.56M +$878K +98,865 +25%
UBS AM
32
UBS AM
Illinois
$4.86M +$208K +23,425 +6%
CBA
33
Coastal Bridge Advisors
Connecticut
$4.58M – – –
RPAM
34
Rhenman & Partners Asset Management
Sweden
$3.99M +$3.11M +350,000 New
Mirae Asset Global Investments
35
Mirae Asset Global Investments
South Korea
$3.72M +$999K +112,565 +53%
LOAMS
36
Lombard Odier Asset Management (Switzerland)
Switzerland
$3.48M -$1.74M -195,966 -39%
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$3.23M -$6.23M -701,412 -71%
CSS
38
Cubist Systematic Strategies
Connecticut
$3.13M +$610K +68,767 +33%
TLP
39
Tri Locum Partners
New York
$3.1M +$2.42M +272,123 New
Bank of America
40
Bank of America
North Carolina
$3.06M -$2.77M -311,934 -54%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$2.83M -$452K -50,866 -17%
Principal Financial Group
42
Principal Financial Group
Iowa
$2.75M +$36.2K +4,074 +2%
Citigroup
43
Citigroup
New York
$2.75M +$1.08M +121,800 +102%
EVM
44
Eaton Vance Management
Massachusetts
$2.7M – – –
GCM
45
Graham Capital Management
Connecticut
$2.68M +$808K +91,040 +63%
Rafferty Asset Management
46
Rafferty Asset Management
New York
$2.53M -$3.07M -346,059 -61%
GC
47
Gratus Capital
Georgia
$2.44M +$102K +11,546 +6%
Swiss National Bank
48
Swiss National Bank
Switzerland
$2.3M +$146K +16,400 +9%
PP
49
PDT Partners
New York
$2.25M -$389K -43,873 -18%
Mitsubishi UFJ Asset Management
50
Mitsubishi UFJ Asset Management
Japan
$1.96M +$134K +15,042 +10%
1
2
3 4 5

ALLO Hedge Fund Activity: Q2 2022 in Review

161 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2022, worth a combined $1.15B — up 38% from $835M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ALLO and 13 opened new positions — a net loss of 16 holders — while 51 trimmed existing stakes and 64 added.

The largest buyer was Woodline Partners, adding an estimated $48.2M. The largest seller was Citadel Advisors, cutting an estimated $22.5M.

  • 161 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2022, down from 180 in Q1 2022.
  • Funds reported $1.15B of Allogene Therapeutics stock for Q2 2022, up 38% quarter-over-quarter.
  • 13 funds opened new Allogene Therapeutics positions in Q2 2022 and 29 closed out, a net change of -16 holders.
  • The largest Allogene Therapeutics buyer in Q2 2022 was Woodline Partners, an estimated $48.2M added.
  • The largest Allogene Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $22.5M sold.

Based on aggregated 13F filings for Q2 2022.